The FDA on February 26, 2016 approved AFINITOR® for the treatment of adult patients with progressive, well-differentiated non-functional, neuroendocrine tumors (NET) of gastrointestinal (GI) or lung origin with unresectable, locally advanced or metastatic disease. AFINITOR® is a product of Novartis Pharmaceuticals Corporation.
Bottom Ad
Advertisement
Subscribe
